Search

everythinglearnresearchcommunity

for

Search:↓

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

Propranolol affects heart rate and renin levels in minoxidil-treated patients.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Antiandrogens are somewhat effective in reducing excessive hair growth in women.

Fexofenadine may help treat a difficult type of hair loss.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Finasteride is an effective and well-tolerated treatment for hirsutism.

Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.

The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Minoxidil controls blood pressure effectively, but may cause side effects like hypertrichosis.

The document concludes that there are no reliable treatments for frontal fibrosing alopecia, with only temporary benefits from current options.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Certain antiparasitics and antidepressants show promise for treating cryptococcosis, especially when combined with fluconazole.

Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

The document concluded that various dermatological treatments have different effectiveness and side effects, with some causing irritation, allergic reactions, or systemic effects.

Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.